Teladoc Health Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Teladoc Health Inc trades at $5.79 (market cap $1.09B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Ermenegildo Zegna N.V. Ordinary Shares is far larger — about 3.2× Teladoc Health Inc's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| TDOC | ZGN | |
|---|---|---|
Market Cap | $1.09B | $3.48B |
Volume | 4,279,268 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.72 | $15.25 |
52-Week Low | $4.47 | $8.69 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $1.35B | $4.43B |
Dividend Yield | — | 1.06% |
Signals from Pluang's Aura AI — not financial advice
Teladoc Health (TDOC) trades at $5.81, down 1.86% on the day, with a bearish technical signal and mixed quarterly earnings performance. The company maintains strong gross margins at 68.97% but continues to report net losses, with a -7.13% net income margin for 2025. Recent developments include new executive appointments and ongoing legal investigations, while analyst consensus shows 35.71% buy ratings with a $8.83 price target.
TDOC presents a turnaround opportunity with attractive valuation metrics (P/S 0.43, EV/EBITDA 6.28) and positive cash flow from operations, but faces significant execution risks from persistent losses, BetterHelp segment challenges, and legal scrutiny. The stock trades near multi-year lows, offering potential upside if management can stabilize the business and return to profitability.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →